115450 — HLB Therapeutics Share Price
Last trade - 00:00- KR₩258bn
- KR₩310bn
- KR₩70bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.79 | ||
| Price to Tang. Book | 6.83 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 4.01 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -8.89% | ||
| Return on Equity | -12.23% | ||
| Operating Margin | -23.7% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | KR₩m | 43,586.41 | 42,402.74 | 52,590.56 | 54,931.94 | 69,561.35 | n/a | n/a | 10.13% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
HLB Therapeutics Co Ltd is a Korea-based company principally engaged in the vaccine medicine products distribution business. The Company operates its business through two segments. The Cold Chain segment mainly engages in the temperature-sensitive vaccine and biopharmaceuticals distribution, distribution process management and temperature maintaining business. The Electronics Business segment engages in the distribution of pumps, motors and transformers used in home gas boilers or water heaters. The Company also operates logistics center.
Directors
- Yil Park CCE (48)
- Won Seok Yang CCE (57)
- Bon Ju Gu OTH (39)
- Byeong Gi Kim OTH (44)
- Sang Gi Lee OTH (49)
- Hun Sik Kim DRC (55)
- Gyeong Bong Ri DRC (33)
- Jong Hyo Yoon DRC (51)
- Se Hui Park NID (37)
- Last Annual
- December 31st, 2025
- Last Interim
- June 30th, 2026
- Incorporated
- June 7th, 2000
- Public Since
- March 26th, 2010
- No. of Shareholders
- 54,460
- No. of Employees
- 89
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Korea Exchange - KOSDAQ
- Shares in Issue
- 94,242,184
- Address
- Room 202, 2nd floor, 6, Sanmaru-ro, GURI, 11902
- Web
- https://hlbtherapeutics.co.kr
- Phone
- +82 317867800
- Auditors
- Samjung Accounting Corporation
Latest News for 115450
Upcoming Events for 115450
Q3 2026 HLB Therapeutics Co Ltd Earnings Release
Q4 2026 HLB Therapeutics Co Ltd Earnings Release
HLB Therapeutics Co Ltd Annual Shareholders Meeting
Similar to 115450
AbClon
Korea Exchange - KOSDAQ
ADBiotech
Korea Exchange - KOSDAQ
AHN-GOOK PHARMACEUTICAL
Korea Exchange - KOSDAQ
Alteogen
Korea Exchange - KOSDAQ
AMINOLOGICS
Korea Exchange - KOSDAQ
FAQ
As of Today at 21:08 UTC, shares in HLB Therapeutics are trading at KR₩2,740. This share price information is delayed by 15 minutes.
Shares in HLB Therapeutics last closed at KR₩2,740 and the price had moved by -10.54% over the past 365 days. In terms of relative price strength the HLB Therapeutics share price has underperformed the FTSE Developed Asia Pacific Index by -33.56% over the past year.
The overall consensus recommendation for HLB Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreHLB Therapeutics does not currently pay a dividend.
HLB Therapeutics does not currently pay a dividend.
HLB Therapeutics does not currently pay a dividend.
To buy shares in HLB Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of KR₩2,740, shares in HLB Therapeutics had a market capitalisation of KR₩258bn.
Here are the trading details for HLB Therapeutics:
- Country of listing: Korea, Republic of
- Exchange: KOE
- Ticker Symbol: 115450
Based on an overall assessment of its quality, value and momentum HLB Therapeutics is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in HLB Therapeutics is KR₩47,000. That is 1615.33% above the last closing price of KR₩2,740.
Analysts covering HLB Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like HLB Therapeutics. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -20.78%.
As of the last closing price of KR₩2,740, shares in HLB Therapeutics were trading +3.16% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The HLB Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at KR₩2,740.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
HLB Therapeutics' management team is headed by:
- Yil Park - CCE
- Won Seok Yang - CCE
- Bon Ju Gu - OTH
- Byeong Gi Kim - OTH
- Sang Gi Lee - OTH
- Hun Sik Kim - DRC
- Gyeong Bong Ri - DRC
- Jong Hyo Yoon - DRC
- Se Hui Park - NID